The potential of Imetelstat has caused much speculation (e.g., https://seekingalpha.com/instablog/3163201-medtechbio/5164810-upcoming-catalysts-can-launch-geron-15-per-share; obtained on 5-26-2018).
There is currently much research being done on imtelestat that has advanced into phase three status (see https://clinicaltrials.gov/ct2/show/NCT02598661?term=imetelstat&rank=4; obtained on 5-27-18).
The Author is a current shareholder of Geron which supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies.
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2018 The Hygiology Post ®